ArticlePloS one2014
Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Statins as Repurposed Drugs in Gynecological Cancer: A Review.International journal of molecular sciences · 2022Pooled it
- Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis.Journal of preventive medicine and hygiene · 2020Pooled it
- Impact of statin use on cancer-specific mortality and recurrence: A meta-analysis of 60 observational studies.Medicine · 2020Pooled it
- Impact of postdiagnostic statin use on ovarian cancer mortality: A systematic review and meta-analysis of observational studies.British journal of clinical pharmacology · 2018Pooled it
- Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis.PloS one · 2015Pooled it
- Cholesterol Metabolism: An Ally in the Development and Progression of Cervical Cancer.International journal of molecular sciences · 2026Review
- Cholesterol metabolism and cancer: Molecular mechanisms, immune regulation and an epidemiological perspective (Review).International journal of molecular medicine · 2025Review
- Dysregulation of Cholesterol Homeostasis in Ovarian Cancer.Current oncology (Toronto, Ont.) · 2023Review
- Statin use improves the prognosis of ovarian cancer: An updated and comprehensive meta-analysis.Oncology letters · 2023Article
- Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.Leukemia & lymphoma · 2022Article
- Advances in ovarian cancer treatment using a combination of statins with other drugs.Frontiers in pharmacology · 2022Review
- Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling.Cells · 2021Article
- Host CYP27A1 expression is essential for ovarian cancer progression.Endocrine-related cancer · 2019Article
- ADP-ribosylation factor-like 4C predicts worse prognosis in endometriosis-associated ovarian cancers.Cancer biomarkers : section A of Disease markers · 2019Article
- Article
- Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment.Frontiers in endocrinology · 2018Review
- Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment.Frontiers in endocrinology · 2018Review
- Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.Cancer prevention research (Philadelphia, Pa.) · 2017Article
- Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimTo determine whether statin use is associated with improved epithelial ovarian cancer (OvCa) survival.
methodsThis is a single-institution retrospective cohort review of patients treated for OvCa between 1992 and 2013. Inclusion criteria were International Federation of Gynecology and Obstetrics (FIGO) stage I-IV OvCa. The primary exposures analyzed were hyperlipidemia and statin use. The primary outcomes were progression-free survival (PFS) and disease-specific survival (DSS).
results442 patients met inclusion criteria. The cohort was divided into three groups: patients with hyperlipidemia who used statins (n = 68), patients with hyperlipidemia who did not use statins (n = 28), and patients without hyperlipidemia (n = 346). OvCa outcomes were evaluated. When we analyzed the entire cohort, we found no significant differences in PFS or DSS among the groups. The median PFS for hyperlipidemics using statins, hyperlipidemics not using statins, and non-hyperlipidemics was 21.7, 13.6, and 14.7 months, respectively (p = 0.69). Median DSS for hyperlipidemics using statins, hyperlipidemics not using statins, and non-hyperlipidemics was 44.2, 75.7, and 41.5 months, respectively (p = 0.43). These findings did not change after controlling for confounders. However, a secondary analysis revealed that, among patients with non-serous-papillary subtypes of OvCa, statin use was associated with a decrease in hazards of both disease recurrence (adjusted HR = 0.23, p = 0.02) and disease-specific death (adjusted HR = 0.23, p = 0.04). To augment the findings in the retrospective cohort, the histology-specific effects of statins were also evaluated in vitro using proliferation assays. Here, statin treatment of cell lines resulted in a variable level of cytotoxicity.
conclusionStatin use among patients with non-serous-papillary OvCa was associated with improvement in both PFS and DSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.